Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Olivia Brayer
CANT
Olivia Brayer
Cantor Fitzgerald
Wall Street Analyst
★★★☆☆
#1547
on 13Foresight · ranked by our own returns
52%
Success Rate
+11.0%
Average Return
11 of 21 calls profitable · -4.2% vs benchmark
📈 Across the calls we could measure, roughly 52% of Olivia Brayer's ratings turned a profit when each position was held for 1 year — averaging +11.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 4 Hold 0 Sell
Olivia's Stock Coverage 21 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
INSM
Insmed
 Jun 10, 2026 BUY Strong Buy
+82.2% avg upside
36 analysts
$235.00
145.33% Upside
 +7.1%
CNTB
Connect Biopharma Holdings
 May 21, 2026 BUY Strong Buy
+226.3% avg upside
11 analysts
$4.00
100.04% Upside
 -0.9%
IKT
Inhibikase Therapeutics
 May 18, 2026 BUY Strong Buy
+231.2% avg upside
8 analysts
$4.00
118.64% Upside
 ·
PTHS
Pelthos Therapeutics
 Apr 01, 2026 BUY Strong Buy
+95.7% avg upside
8 analysts
$50.00
72.44% Upside
 +21.1%
CTMX
CytomX Therapeutics
 Mar 20, 2026 BUY Strong Buy
+269.6% avg upside
21 analysts
$12.00
306.83% Upside
 -32.4%
GOSS
Gossamer Bio
 Mar 20, 2026 HOLD Buy
+4379.4% avg upside
17 analysts
 — -19.1%
TENX
Tenax Therapeutics
 Mar 17, 2026 BUY Strong Buy
+213.9% avg upside
8 analysts
$35.00
191.64% Upside
 -18.5%
UTHR
United Therapeutics
 Mar 12, 2026 BUY Buy
-18.7% avg upside
26 analysts
$625.00
16.53% Upside
 +3.5%
BMRN
BioMarin Pharmaceutical
 Mar 02, 2026 BUY Strong Buy
+72.8% avg upside
52 analysts
$85.00
55.32% Upside
 -7.9%
VNDA
Vanda
 Feb 23, 2026 BUY Strong Buy
+254.2% avg upside
13 analysts
$11.00
89.60% Upside
 -22.9%
ALNY
Alnylam Pharma
 Feb 12, 2026 HOLD Strong Buy
+23.6% avg upside
51 analysts
$400.00
43.85% Upside
 -8.3%
MNKD
MannKind
 Mar 20, 2025 BUY Buy
+78.6% avg upside
22 analysts
$9.00
128.45% Upside
 -53.0%
VRTX
Vertex Pharmaceuticals
 Feb 11, 2025 BUY Strong Buy
-2.6% avg upside
61 analysts
$480.00
6.21% Upside
 +1.3%
AMGN
Amgen
 Feb 05, 2025 BUY Buy
-11.6% avg upside
57 analysts
$340.00
0.69% Upside
 +23.4%
BMY
Bristol-Myers Squibb
 Feb 04, 2025 HOLD Buy
+9.1% avg upside
42 analysts
$55.00
1.82% Upside
 +2.4%
GILD
Gilead Sciences
 Nov 06, 2024 HOLD Strong Buy
-4.8% avg upside
66 analysts
$80.00
35.42% Downside
 +38.6%
REGN
Regeneron
 Apr 17, 2024 HOLD Strong Buy
+26.9% avg upside
57 analysts
$925.00
51.74% Upside
 -37.4%
AUPH
Aurinia Pharmaceuticals
 Feb 23, 2024 BUY Strong Buy
-7.2% avg upside
12 analysts
$10.00
39.16% Downside
 +33.3%
OMER
Omeros
 Nov 10, 2023 HOLD Buy
+111.2% avg upside
14 analysts
 — +252.8%
CRSP
Crispr Therapeutics AG
 Oct 17, 2023 HOLD Buy
+39.1% avg upside
41 analysts
 — +10.6%
LENZ
LENZ Therapeutics
 Mar 20, 2023 HOLD Buy
+284.0% avg upside
17 analysts
$3.00
51.17% Downside
 +91.1%
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Olivia Brayer — Frequently Asked Questions
How accurate are Olivia Brayer's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Olivia's ratings were profitable over a one-year hold, with an average return of +11.0% per rating, or -4.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Olivia ranked on 13Foresight?
Olivia Brayer is currently ranked #1547 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Olivia cover?
Olivia most recently has ratings on INSM, CNTB, IKT, PTHS, CTMX, GOSS, TENX, UTHR, BMRN, VNDA, ALNY, MNKD and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.